Efficacy and safety of adjuvant low-dose apatinib combined with SOX regimen versus SOX regimen in patients with resectable locally advanced gastric cancer: a cohort study

ObjectiveApatinib combined with S‐1 and oxaliplatin (SOX) synergistically improves the prognosis of advanced gastric cancer patients, but its application as an adjuvant regimen has rarely been reported. This study aimed to investigate the efficacy and safety of adjuvant low-dose apatinib combined wi...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Liang Wang, Chenming Feng, Yi Nan, Yanjun Xu, Chao Zhang, Weipeng Wu, Yafei Duan, Haodong Zhang, Qiang Zhao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-03-01
Edice:	Frontiers in Pharmacology
Témata:	adjuvant therapy apatinib disease-free survival gastric cancer S‐1 and oxaliplatin
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1670012/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!